Cover Image
市場調查報告書

中國的人體疫苗產業

China Human Vaccine Industry Report, 2017-2021

出版商 ResearchInChina 商品編碼 242708
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的人體疫苗產業 China Human Vaccine Industry Report, 2017-2021
出版日期: 2017年07月18日 內容資訊: 英文 130 Pages
簡介

由於疫苗可有效預防和抑制感染疾病,對生物製藥的需求堅實。2013年,中國的人體疫苗的批次放行量與前一年同期比較增加4.9%,市場規模與前一年同期比較增加2.8%,達成成長,不過,2014年一變,與前一年同期比較減少2.4%成為了7億9,100萬噸。這是因為懷疑因疫苗發生的死亡事故,由於大數公司未合格新檢驗標準的影響而中止了疫苗的開發。

本報告提供中國的人體疫苗產業調查分析、產業概要、產業與市場、各市場區隔、進出口、主要製造商等相關的系統性資訊。

第1章 疫苗產業概要

  • 定義與分類
  • 產業鏈

第2章 中國的人體疫苗產業與市場

  • 概要
  • 營運環境
    • 國際市場
    • 政策環境
  • 現狀
  • 需求與供給
  • 競爭格局
  • 趨勢
  • 銷路

第3章 中國的人體疫苗市場

  • 需求與供給、競爭格局、市場價格等
    • B型肝炎疫苗
    • 腦膜炎疫苗
    • A型肝炎疫苗
    • 流感疫苗
    • Hib疫苗
    • 狂犬病(恐水症)疫苗
    • 水痘疫苗
    • 肺炎球菌疫苗
    • DTP疫苗
    • 小兒麻庳疫苗

第4章 中國的疫苗進出口

  • 出口
  • 進口

第5章 中國的主要疫苗廠商

  • 簡介、經營、收益結構等
    • China National Biotec Group
    • Hualan Biological Engineering Inc.
    • Chongqing Zhifei Biological Products Co., Ltd
    • Walvax Biotechnology Co., Ltd
    • Sinovac Biotech Ltd.
    • Liaoning Chengda Co., Ltd.
    • Changchun BCHT Biotechnology Co. Ltd.
    • Changchun Changsheng Life Sciences Limited
    • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd
    • Shenzhen Kangtai Biological Products Co. Ltd
    • Dalian Hissen Bio-Pharm Co., Ltd
    • NCPC GeneTech Biotechnology Development Co., Ltd.
    • Beijing Minhai Biotechnology Co., Ltd.
    • Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
    • Jiangsu Simcere Vaxtec Bio-pharmaceutical Co., Ltd.

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: ZLC052

The human vaccine industry presented the following main characteristics in 2016 in China:

1. Lot release volume of human vaccines declined.

Affected by the illegal vaccine case in Mar 2016 in Shandong, the country's lot release volume of human vaccines came to 553.6 million doses through the year 2016, down 3.8% over the previous year. The lot release volume of ten vaccines (Hepatitis B vaccine, Diphtheria, Tetanus and acellular Pertussis combined vaccine (adsorbed), rabies vaccine, Japanese encephalitis vaccine, poliomyelitis vaccine, meningococcal vaccine, measles and rubella combined attenuated live vaccine, MMR combined attenuated live vaccine, influenza vaccine, and Hepatitis A Vaccine) was relatively higher, totaling 467.2 million doses, 84.4% of the country's total, a year-on-year 1.4% drop.

2. The industry was highly concentrated.

The Chinese human vaccine market had been highly concentrated, primarily dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, and Changchun Institute of Biological Products under China National Biotec Group Company Limited. In 2016, China National Biotec Group accounted for 52.6% of the country's lot release volume of human vaccines, compared with a small fraction of market share for Liaoning Chengda Biotechnology, Changsheng Bio-technology, Shenzhen Kangtai Biological Products, Chongqing Zhifei Biological Products, Beijing Minhai Biotechnology, Walvax Biotechnology, Changchun BCHT Biotechnology, Hualan Biological Engineering, Zhejiang Tianyuan Bio-Pharmaceutical, and Sinovac Biotech.

3. Vaccine enterprises scaled up R&D efforts.

Major Chinese vaccine enterprises have intensified their efforts for R&D in order to enhance overall competitiveness in recent years. Walvax Biotechnology has started HPV-2 industrialization project and is expected to launch the product in 2019, and meanwhile has put its 13-valent pneumococcal combined vaccine in phase III clinical trial and is predicted to bring the product to the market in 2018 or 2019. Launching of new vaccines will make the company more competitive.

4. Two-child policy, population aging, and new vaccines were drivers of the industry.

Along with full implementation of the two-child policy in Oct 2015, the country's newborns increased sharply to 17.86 million in 2016 and will remain above 18 million each year over the next five years. Meanwhile, the population aged 60 and over reached 230.9 million by the end of 2016 and is expected to hit 245.3 million by 2021. In addition, some domestic enterprises have set about developing new vaccines like HPV vaccine and 13-valent pneumococcal vaccine which are expected to be available on the market in 2018 or 2019.

Pushed by the two-child policy, population aging, and launching of new vaccines, the vaccine industry in China will grow rapidly with an estimated market size of up to RMB31.2 billion in 2021.

China Human Vaccine Industry Report, 2017-2021 highlights the following:

  • Human vaccine industry in China (operating environment, status quo, market demand, market size, circulation channel, import & export, competitive landscape, development trends, etc.);
  • Analysis on Chinese human vaccine market segments(like Hepatitis B Vaccine, Meningococcal Vaccine, Hepatitis A vaccine, Influenza Vaccine, Hib Vaccine, Rabies Vaccine, Varicella Vaccine, Pneumococcal Vaccines, DTP Vaccine, Poliomyelitis Vaccine, Hepatitis E Vaccine), including market demand, lot release volume, competitive landscape, etc.;
  • 19 local vaccine enterprises (operation, gross margin, major customers, R&D and investment, development and forecast, etc.).

Table of Contents

1. Overview of Vaccine Industry

  • 1.1. Definition & Classification
  • 1.2. Industry Chain

2. China Human Vaccine Industry Development Analysis

  • 2.1. Operating Environment
    • 2.1.1. International Market
    • 2.1.2. Policy Environment
    • 2.1.3. Biopharmaceutical Market
  • 2.2. Status Quo
  • 2.3. Supply & Demand
  • 2.4. Market Size
  • 2.5. Circulation Channel
  • 2.6. Import & Export
    • 2.6.1. Import
    • 2.6.2. Export
    • 2.6.3. Average Price
  • 2.7. Competition Pattern
  • 2.8. Development Trend
    • 2.8.1. Vaccine for Cervical Cancer Prevention is expected to be launched in China
    • 2.8.2. Domestic Pneumococcal 13-valent Conjugate Vaccine is Expected to be launched
    • 2.8.3. Two-child Policy Favorable to Industry Development
    • 2.8.4. Aging population propel industry development to some extent
    • 2.8.5. Industry scale rises stably

3. Human Vaccine Market Segments in China

  • 3.1. Hepatitis B Vaccine
    • 3.1.1. Supply & Demand
    • 3.1.2. Lot Release Volume
    • 3.1.3. Competition Pattern
  • 3.2. Meningococcal Vaccine
    • 3.2.1. Supply & Demand
    • 3.2.2. Lot Release Volume
    • 3.2.3. Competition Pattern
  • 3.3. Hepatitis A Vaccine
    • 3.3.1. Supply & Demand
    • 3.3.2. Lot Release Volume
    • 3.3.3. Competition Pattern
  • 3.4. Influenza Vaccine
    • 3.4.1. Supply & Demand
    • 3.4.2. Lot Release Volume
    • 3.4.3. Competition Pattern
  • 3.5. Hib Vaccine
    • 3.5.1. Supply & Demand
    • 3.5.2. Lot Release Volume
    • 3.5.3. Competition Pattern
    • 3.5.4. Market Forecast
  • 3.6. Human Rabies Vaccine
    • 3.6.1. Supply & Demand
    • 3.6.2. Lot Release Volume
    • 3.6.3. Competition Pattern
  • 3.7. Varicella Vaccine
    • 3.7.1. Supply & Demand
    • 3.7.2. Lot Release Volume
    • 3.7.3. Competition Pattern
  • 3.8. Pneumococcal Vaccines
    • 3.8.1. Supply & Demand
    • 3.8.2. Lot Release Volume
    • 3.8.3. Competition Pattern
  • 3.9. DTP Vaccine
    • 3.9.1. Supply & Demand
    • 3.9.2. Lot Release Volume
    • 3.9.3. Competition Pattern
  • 3.10. Poliomyelitis Vaccine
    • 3.10.1. Supply & Demand
    • 3.10.2. Lot Release Volume
    • 3.10.3. Competition Pattern
  • 3.11. Hepatitis E Vaccine
    • 3.11.1. Supply & Demand
    • 3.11.2. Lot Release Volume
    • 3.11.3. Competition Pattern

4. Major Vaccine Manufacturers in China

  • 4.1. China National Biotec Group
    • 4.1.1. Profile
    • 4.1.2. Beijing Tiantan Biological Products Co., Ltd
    • 4.1.3. Chengdu Institute of Biological Products Co., Ltd.
    • 4.1.4. Shanghai Institute of Biological Products Co., Ltd.
    • 4.1.5. Wuhan Institute of Biological Products Co., Ltd.
    • 4.1.6. Lanzhou Institute of Biological Products Co., Ltd.
    • 4.1.7. Changchun Institute of Biological Products Co., Ltd.
  • 4.2. Beijing Tiantan Biological Products Co., Ltd.
    • 4.2.1. Profile
    • 4.2.2. Operation
    • 4.2.3. Revenue Structure
    • 4.2.4. Gross Margin
    • 4.2.5. R&D Cost and Investment
    • 4.2.6. Clients
    • 4.2.7. Vaccine Business
    • 4.2.8. Development and Prospects
  • 4.3. Hualan Biological Engineering Inc.
    • 4.3.1. Profile
    • 4.3.2. Operation
    • 4.3.3. Revenue Structure
    • 4.3.4. R&D Cost and Investment n
    • 4.3.5. Clients
    • 4.3.6. Vaccine Business
    • 4.3.7. Development and Prospects
  • 4.4. Chongqing Zhifei Biological Products Co., Ltd.
    • 4.4.1. Profile
    • 4.4.2. Operation
    • 4.4.3. Revenue Structure
    • 4.4.4. Gross Margin
    • 4.4.5. Major Clients
    • 4.4.6. R&D Cost and Investment
    • 4.4.7. Development and Prospects
  • 4.5. Walvax Biotechnology Co, Ltd.
    • 4.5.1. Profile
    • 4.5.2. Operation
    • 4.5.3. Revenue Structure
    • 4.5.4. Gross Margin
    • 4.5.5. Major Clients
    • 4.5.6. R&D Cost and Investment
    • 4.5.7. Vaccine Business
    • 4.5.8. Development and Prospects
  • 4.6. Liaoning Cheng Da Co., Ltd.
    • 4.6.1. Profile
    • 4.6.2. Operation
    • 4.6.3. Revenue Structure
    • 4.6.4. Gross Margin
    • 4.6.5. Clients
    • 4.6.6. R&D Cost and Investment
    • 4.6.7. Development and Prospects
  • 4.7. Shenzhen Kangtai Biological Products Co., Ltd.
    • 4.7.1. Profile
    • 4.7.2. Operation
    • 4.7.3. Revenue Structure
    • 4.7.4. Gross Margin
    • 4.7.5. Clients
    • 4.7.6. R&D Cost and Investment
    • 4.7.7. Development and Prospects
  • 4.8. Changchun Changsheng Life Sciences Limited
    • 4.8.1. Profile
    • 4.8.2. Operation
    • 4.8.3. Revenue Structure
    • 4.8.4. R&D Cost and Investment
    • 4.8.5. Development and Prospects
  • 4.9. Sinovac Biotech Ltd.
    • 4.9.1. Profile
    • 4.9.2. Operation
    • 4.9.3. Revenue Structure
    • 4.9.4. Sinovac Biotech (Beijing)
  • 4.10. Changchun BCHT Biotechnology Co. Ltd.
    • 4.10.1. Profile
    • 4.10.2. Operation
    • 4.10.3. Development Dynamics
  • 4.11. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
    • 4.11.1. Profile
    • 4.11.2. Operation
  • 4.12. Dalian Hissen Bio-Pharm Co., Ltd.
    • 4.12.1. Profile
  • 4.13. NCPC GeneTech Biotechnology Development Co., Ltd.
    • 4.13.1. Profile
    • 4.13.2. Operation
  • 4.14. Dalian Aleph Biomedical Co., Ltd.
    • 4.14.1. Profile
    • 4.14.2. Development Dynamics
  • 4.15. Beijing Minhai Biotechnology Co., Ltd.
    • 4.15.1. Profile
    • 4.15.2. Operation
  • 4.16. Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
    • 4.16.1. Profile
    • 4.16.2. Operation
  • 4.17. Other Enterprises
    • 4.17.1. Jiangsu SimcereVaxtec Bio-pharmaceutical Co., Ltd.
    • 4.17.2. Xiamen Innovax Biotech CO., LTD.
    • 4.17.3. Convac Biotechnology Co., Ltd.

Selected Charts:

  • Classification of Vaccines
  • Vaccine Industry Chain
  • Global Human Vaccine Market Size, 2010-2016
  • Global Human Vaccine Market Size, 2016-2021E
  • Revenue of Top 5 Vaccine Companies, 2008-2016
  • Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005- 2015
  • Policies in Vaccine Industry, 2016-2017
  • Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2016
  • Gross Industrial Output Value of China Biopharmaceutical Industry, 2016-2021E
  • EPI Human Vaccine Varieties in China
  • Lot Release Volume of Human Vaccine in China, 2013-2017
  • Top10 Human Vaccines by Lot Release Volume in China, 2015-2016
  • Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, 2016
  • Provinces Completing Online Publicity of Vaccine Procurement in China by the End of Mar 2017
  • China Human Vaccine Market Size, 2010-2016
  • Import Volume and Value of Human Vaccine in China, 2010-2017
  • China's Human Vaccine Import Volume and Value by Country, 2016
  • Export Volume and Value of Human Vaccine in China, 2010-2017
  • Top 10 Countries/Regions of China Human Vaccine Export
  • Average Unit Export/Import Price of Human Vaccine in China, 2010-2017
  • Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2016
  • Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2017H1
  • Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2015-2017
  • Lot Release Volume of Vaccines in China by Enterprise, 2016
  • Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2016
  • Market Share of Human Vaccine Industry in China by Enterprise, 2016
  • R&D Projects and Progress of Major Vaccine Enterprises in China by the End of 2016
  • Morbidity of Cervical Cancer Worldwide
  • Global HPV Vaccines
  • Global HPV Vaccine Market Size, 2006-2015
  • Shanghai Zerun Biotechnology's Progress in R&D of HPV Vaccine
  • China's Newborns, 2015-2021E
  • Population Aged 60 and Over in China, 2009-2021E
  • Chinese Vaccine Market Size, 2016-2021E
  • Hepatitis B Morbidity and Mortality in China, 2013-2016
  • Lot Release Volume of Hepatitis B Vaccine in China, 2015-2017
  • Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2015-2017
  • Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2015-2017
  • Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2015-2017
  • Meningitis Morbidity and Mortality in China, 2013-2016
  • Meningococcal Vaccines Lot Release Volume in China, 2015-2017
  • Meningococcal Vaccines Lot Release Volume in China by Type, 2015-2017
  • Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2015-2017
  • Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2015-2017
  • Hepatitis A Morbidity and Mortality in China, 2013-2016
  • Lot Release Volume of Hepatitis A Vaccine in China, 2015-2017
  • Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2015-2017
  • Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2015-2017
  • H7N9 Influenza Morbidity and Mortality in China, 2013-2016
  • Lot Release Volume of Influenza Vaccine in China, 2015-2016
  • Lot Release Volume of Major Influenza Vaccine Companies in China, 2015-2016
  • Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2015-2016
  • Lot Release Volume of Hib Vaccine in China, 2015-2017
  • Lot Release Volume of Major Hib Vaccine Companies in China, 2015-2017
  • Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2015-2017
  • Rabies Morbidity and Mortality in China, 2013-2016
  • Lot Release Volume of Human Rabies Vaccine in China, 2015-2017
  • Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2015-2017
  • Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2015-2017
  • Lot Release Volume of Varicella Vaccine in China, 2015-2017
  • Lot Release Volume of Major Varicella Vaccine Companies in China, 2015-2017
  • Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2015-2017
  • Lot Release Volume of Pneumococcal Vaccines in China, 2015-2017
  • Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2015-2017
  • Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2015-2017
  • Pertussis Morbidity and Mortality in China, 2012-2016
  • Neonatal Tetanus Morbidity and Mortality in China, 2012-2016
  • Lot Release Volume of DTP Vaccine in China, 2015-2017
  • Lot Release Volume of Major DTP Vaccine Companies in China, 2015-2017
  • Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2015-2017
  • Poliomyelitis Morbidity and Mortality in China, 2011-2016
  • Lot Release Volume of Poliomyelitis Vaccine in China, 2015-2017
  • Lot Release Volume of Major Poliomyelitis Vaccine Companies in China, 2015-2017
  • Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2015-2017
  • Hepatitis E Morbidity and Mortality in China, 2012-2016
  • Lot Release Volume of Hepatitis E Vaccine in China, 2015-2016
  • Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2015-2016
  • Vaccine Varieties of Chengdu Institute of Biological Products
  • Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2015-2017
  • Vaccine Varieties of Shanghai Institute of Biological Products
  • Operation of Shanghai Institute of Biological Products, 2013-2016
  • Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2015-2017
  • Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2015-2017
  • Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2015-2017
  • Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2015-2017
  • Revenue and Net Income of Beijing Tiantan Biological Products, 2013-2017
  • Revenue Breakdown of Beijing Tiantan Biological Products by Product, 2013-2016
  • Revenue Structure of Beijing Tiantan Biological Products by Product, 2013-2016
  • Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2013-2016
  • Revenue Structure of Beijing Tiantan Biological Products by Region, 2013-2016
  • Gross Margin of Beijing Tiantan Biological Products by Product, 2013-2016
  • R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2013-2016
  • Main R&D Projects of Beijing Tiantan Biological Products as of the end of 2016
  • Beijing Tiantan Biological Products' Revenue from Top5 Customers and % of Total Revenue, 2012-2016
  • Vaccine Revenue and Percentage of Beijing Tiantan Biological Products, 2013-2016
  • Output & Sales Volume of Major Vaccine Products of Beijing Tiantan Biological Products, 2016
  • Bidding Status of Beijing Tiantan Biological Products in Centralized Procurement Bidding, 2016
  • Revenue and Operating Income of Beijing Tiantan Biological Products, 2016-2021E
  • Revenue and Net Income of Hualan Biological Engineering, 2013-2017
  • Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2016
  • Revenue Structure of Hualan Biological Engineering by Sector, 2013-2016
  • R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2016
  • Hualan Biological Engineering's Revenue from Top5 Customers and % of Total Revenue, 2013-2016
  • Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2016
  • Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2016
  • Major Products and Application of Chongqing Zhifei Biological Products
  • Major Subsidiaries of Chongqing Zhifei Biological Products
  • Revenue and Net Income of Chongqing Zhifei Biological Products, 2012-2017
  • Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2016
  • Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2016
  • Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2014-2016
  • Gross Margin of Chongqing Zhifei Biological Products by Product, 2013-2016
  • Chongqing Zhifei Biological Products' Revenue from Top5 Customers and % of Total Revenue, 2011-2016
  • R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2011-2016
  • Projects under Registration Process of Chongqing Zhifei Biological Products, 2016
  • Progress of Preclinical Projects of Chongqing Zhifei Biological Products by the end of 2016
  • Revenue and Operating Income of Chongqing Zhifei Biological Products, 2016-2021E
  • Revenue and Net Income of Walvax Biotechnology, 2013-2017
  • Revenue Breakdown of Walvax Biotechnology by Product, 2014-2016
  • Revenue Breakdown of Walvax Biotechnology by Region, 2014-2016
  • Gross Margin of Walvax Biotechnology by Product, 2013-2016
  • Walvax Biotechnology's Revenue from Top5 Customers and % of Total Revenue, 2015-2016
  • R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2016
  • Progress of Products under Registration Declaration of Walvax Biotechnology as of the end of Mar.2017
  • Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2016
  • Lot Release Volume of Walvax Biotechnology, 2014-2016
  • Revenue and Operating Income of Walvax Biotechnology, 2016-2021E
  • Revenue and Net Income of Liaoning Chengda, 2013-2016
  • Revenue Breakdown of Liaoning Chengda by Sector, 2013-2016
  • Revenue Structure of Liaoning Chengda by Sector, 2013-2016
  • Gross Margin of Liaoning Chengda, 2013-2016
  • Liaoning Chengda's Revenue from Top5 Customers and % of Total Revenue, 2015-2016
  • R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2016
  • Revenue and Net Income of Liaoning Chengda Biotechnology, 2016-2021E
  • Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2016 Revenue and Net Income of Shenzhen Kangtai Biological Products, 2013-2017
  • Revenue Breakdown of Shenzhen Kangtai Biological Products by Product, 2015-2016
  • Lot Release Volume and Percentage of Shenzhen Kangtai Biological Products, 2015-2016
  • Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2016
  • Gross Margin of Shenzhen Kangtai Biological Products, 2013-2016
  • Shenzhen Kangtai Biological Products' Revenue from Top5 Customers and % of Total Revenue, 2014-2016
  • R&D Costs and % of Total Revenue of Shenzhen Kangtai Biological Products, 2013-2016
  • IPO Fund-Rasing Projects of Shenzhen Kangtai Biological Products
  • Revenue and Net Income of Shenzhen Kangtai Biological Products, 2016-2021E
  • Equity Structure of Changchun Changsheng Life Sciences
  • Revenue and Net Income of Changchun Changsheng Life Sciences, 2014-2017
  • Output & Sales Volume, Inventory of Changchun Changsheng Life Sciences, 2014-2016
  • Revenue Breakdown of Changchun Changsheng Life Sciences by Product,2014-2016 Revenue Structure of Changchun Changsheng Life Sciences by Product, 2014-2016 Revenue Breakdown of Changchun Changsheng Life Sciences by Region, 2014-2016 Revenue Structure of Changchun Changsheng Life Sciences by Region, 2014-2016
  • R&D Costs and % of Total Revenue of Changchun Changsheng Life Sciences, 2014-2016
  • Progress of Projects under R&D of Changchun Changsheng Life Sciences as of the end of 2016
  • Revenue and Net Income of Changchun Changsheng Life Sciences, 2016-2021E
  • Revenue and Net Income of Sinovac Biotech, 2013-2016
  • Revenue Breakdown of Sinovac Biotech by Product, 2013-2016
  • Financial Indices of Sinovac Biotech, 2015-2016
  • Financial Indices of Changchun BCHT Biotechnology, 2014-2016
  • Equity Structure of Zhejiang Tianyuan Bio-Pharmaceutical
  • Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical
  • Revenue and Net Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2016
  • Financial Indices of Zhejiang Tianyuan Bio-Pharmaceutical, 2014-2016
  • Equity Structure of Dalian Aleph Biomedical
  • Financial Indices of Beijing Minhai Biotechnology, 2015-2016
  • Total Assets and Revenue of Shenzhen Sanofi Pasteur Biological Products, 2016
  • Development Course of Xiamen Innovax Biotech
Back to Top